Crews Bank & Trust’s ImmunityBio IBRX Stock Holding History

Crews Bank & Trust’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8K	Buy	1,800 +800	+80%	+$6.05K	﹤0.01%	502
2026 Q1	$7.67K	Buy	+1,000	New	+$6.85K	﹤0.01%	555

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crews Bank & Trust's IBRX Position: Q2 2026 in Review

Crews Bank & Trust increased its ImmunityBio (IBRX) stake by 80% in Q2 2026, buying an estimated $6.05K and bringing the position to 1,800 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

Crews Bank & Trust first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Crews Bank & Trust held 1,800 shares of ImmunityBio worth $15.8K as of Q2 2026.
Crews Bank & Trust bought 800 ImmunityBio shares in Q2 2026, an estimated $6.05K.
ImmunityBio made up ﹤0.01% of Crews Bank & Trust's portfolio in Q2 2026, its #502 holding.
Crews Bank & Trust first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Crews Bank & Trust's 13F filing for Q2 2026, filed 16 Jul 2026.